The chart solidifies you what you already know: Biotech stocks are off to a blistering start in 2014.

The iShares Nasdaq Biotechnology Index ETF (IBB) is trouncing the S&P 500 through the first three weeks of the year.

IBB Chart
IBB data by YCharts

It's hard to imagine, but biotech stocks are starting off 2014 stronger than they did in 2013.

Here's the same IBB vs. S&P 500 comparison as above, but looking at the first 20 calendar days of 2013:


IBB Chart
IBB data by YCharts

The top-performing biotech and drug stocks year to date, according to S&P CapitalIQ:

Intercept Pharma (ICPT - Get Report) +329%
Rexahn Pharma (RNN)+116%
Neurocine Biosciences (NBIX - Get Report) +110%
CorMedix (CRMD - Get Report) +98%
Cell Therapeutics (CTIC - Get Report) +91%

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.